TAO Synergies Inc.

TAO Synergies Inc., formerly known as Synaptogenix, Inc., is a clinical-stage biopharmaceutical company that also operates a cryptocurrency treasury and media initiative. The company primarily develops its lead drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease and other neurodegenerative conditions such as Fragile X syndrome. Additionally, it operates a long-only cryptocurrency treasury strategy focused on accumulating and staking TAO tokens on the Bittensor decentralized artificial intelligence network to generate revenue. The company also produces news, insights, and podcasts covering the Bittensor ecosystem through its TAO Daily platform. Because its biopharmaceutical candidates remain in development, its target beneficiaries include patients with cognitive disorders, alongside participants and investors in the decentralized machine learning sector.

The company's operations originate in the United States, conducting research collaborations and clinical trials with domestic institutions such as Nemours Children's Hospital and the Cleveland Clinic. It maintains a corporate subsidiary, TAOX Florida Inc., to facilitate its digital asset treasury activities. The provided text does not state the company's headquarters location.

Summary of the business section of TAO Synergies's latest annual report, written by StockData.

“As of the date of this Annual Report on Form 10-K, we have four full-time personnel, including three executive officers and one employee who is primarily engaged in administrative activities.”